ABSTRACT

Introduction: Patients affected by Inborn Errors of Immunity (IEI) represent a potential group-at-risk in the current COVID-19 pandemic. Studies on large and small cohorts of IEI reported a huge variability clinical manifestations associated to SARS-Cov-2, ranging from asymptomatic, mild, moderate/severe to death. A great impulse to improve remote assistance programs and to switch to home-based treatment to reduce mobility and face to face contacts has been implemented.

Areas covered: The authors completed a comprehensive review of the literature by searching the PubMed database for studies on large and small cohorts and case reports of IEI patients with COVID-19, with the aim to provide useful information for their clinical management during the COVID-19 pandemic.

Expert opinion: Surprisingly, a low number of IEI patients affected by SARS-Cov-2 were reported with a risk to die for COVID-19 overlapping that of the general population. The low number might be explained by the choice of most physicians to inform early in the pandemic about safety measures, to switch most of the IEI patients to home therapy and to remote assistance. The guidelines issued by the scientific societies and periodically updated, represent the best tool for the clinical management of IEI patients.

抽象的

简介：受先天性免疫错误（IEI）影响的患者代表了当前COVID-19大流行中的潜在高危人群。对IEI的大大小小的研究都报告了SARS-Cov-2相关的巨大变异性临床表现，从无症状，轻度，中度/重度到死亡。已经实现了极大的冲动，以改善远程协助程序并改用家庭式治疗以减少移动性和面对面的接触。

涵盖的领域：作者通过搜索PubMed数据库以进行大样本和小样本研究以及IEI COVID-19的IEI患者的病例报告，从而对文献进行了全面的综述，旨在为COVID- 19大流行。

专家意见：出乎意料的是，据报道，受SARS-Cov-2影响的IEI患者数量很少，死于COVID-19的危险与普通人群相同。人数少的原因可能是大多数医生选择在大流行早期就安全措施提供信息，将大多数IEI患者转为家庭治疗和远程协助。由科学协会发布并定期更新的指南代表了IEI患者临床管理的最佳工具。